SCHEMBL2403259

SCHEMBL2403259

CN(C1CCN1C1=CC(=O)c2nc(-c3cccc(Cl)c3)oc2C1=O)C1CCN1C1=CC(=O)c2nc(-c3cccc(Cl)c3)oc2C1=O

nearest known ligand 0.36

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TP53 P04637 6/20 0.36
HSD11B1 P28845 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
NPC1 O15118 1/20 0.35
MAPT P10636 4/20 0.35
MAOB P27338 2/20 0.35
GAA P10253 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.34
NOTUM Q6P988 1/20 0.34
GPR119 Q8TDV5 1/20 0.34
UCHL1 P09936 1/20 0.33
IKBKB O14920 1/20 0.33
USP2 O75604 1/20 0.33
ALOX15 P16050 1/20 0.33
MAPK1 P28482 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2401752 0.89 RAB9A (0.36) TP53MEN1KMT2ANPC1MAPT
SCHEMBL2398532 0.82 MEN1 (0.33) TP53MEN1KMT2ANPC1MAPT
SCHEMBL2404414 0.82 USP1 (0.44) MAPT
SCHEMBL2401248 0.81 NPSR1 (0.35) TP53MEN1KMT2AMAPTSMN1; SMN2
SCHEMBL2401601 0.79 CDC25A (0.55) USP2
SCHEMBL4859017 0.71 CDC25A (0.63) MAPTMAOBNOTUMALOX15
SCHEMBL4865709 0.70 CDC25A (0.44) MEN1KMT2ANPC1MAPTMAOB
SCHEMBL2403256 0.69 CDC25A (0.52) MAPTMAOBNOTUMALOX15
SCHEMBL5215387 0.68 NOTUM (0.49) TP53NPC1MAPTMAOBSMN1; SMN2
SCHEMBL1919578 0.59 CDC25A (0.56) NPC1MAPTGAASMN1; SMN2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275624-A1 INHIBITORS OF CDC PHOSPHATASES SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2009-11-05 US claimed
EP-1831209-B1 CDC25 PHOSPHATASE INHIBITORS IPSEN PHARMA (FR) 2009-08-12 EP claimed
US-8017637-B2 Inhibitors of cdc phosphatases IPSEN PHARMA S.A.S. (FR) 2011-09-13 US disclosed
US-20090275624-A1 INHIBITORS OF CDC PHOSPHATASES SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2009-11-05 US disclosed
EP-1831209-B1 CDC25 PHOSPHATASE INHIBITORS IPSEN PHARMA (FR) 2009-08-12 EP disclosed
EP-1831209-A2 CDC25 PHOSPHATASE INHIBITORS Société de Conseils de Recherches et d'Applications Scientifiques SAS (S.C.R.A.S) (FR) 2007-09-12 EP disclosed
WO-2006067311-A2 CDC25 PHOSPHATASE INHIBITORS SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) SAS (FR) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275624-A1 INHIBITORS OF CDC PHOSPHATASES CDC25C, CDC25A, CDC25B TP53 292/4885HSD11B1 2493/4885MEN1 1555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.